Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

Completed · Phase 4

Conditions studied: HIV Infections, Hemophilia A

In brief

The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.

Key facts

Study ID

NCT00002386

Run by

Merck Sharp & Dohme LLC

People needed

55

Last updated by the study team

2005-06-24

Who can join

Age: 16 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• You may be eligible for this study if you:
• Are an HIV-positive male.
• Have been diagnosed with hemophilia.
• Have been taking clotting factors for hemophilia for at least 6 months.
• Have been taking a combination of one protease inhibitor plus two other anti-HIV drugs for at least 6 months, or have never taken a protease inhibitor.
• Are at least 16 years old (consent of parent or guardian required if under 18).

Where it is running

• USCF — San Francisco, California, United States
• Georgetown U Med Ctr / Div of Hematology / Oncology — Washington D.C., District of Columbia, United States
• Emory Univ — Atlanta, Georgia, United States
• Riley Hosp for Children — Indianapolis, Indiana, United States
• Tulane Univ School of Medicine / Hematology / Oncology — New Orleans, Louisiana, United States
• Univ of North Carolina School of Medicine / Div Hemat / Onco — Chapel Hill, North Carolina, United States
• Milton Hershey Med Ctr — Hershey, Pennsylvania, United States
• Montreal Gen Hosp — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.